在肌缩侧面硬化症中治疗脱节症的管理
Elena Pasqualucci1, Diletta Angeletti1, Pamela Rosso2
1Department of Sense Organs, Sapienza University of Rome, 00161 Rome, Italy.
Cells
|July 25, 2025
概括
肌缩性侧面硬化症 (ALS) 导致肌痛性关节炎,影响患者的生活质量. 通过数字语音生物标志物和人工智能分析进行早期检测,可以及时进行干预,以改善语音功能和沟通.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 语音语言病理学 语言病理学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种渐进的运动神经元疾病.
- 脱发性关节障碍是ALS的常见和衰弱的症状,特别是在圆柱形状.
- 语音障碍显著影响患者的生活质量和沟通.
研究的目的:
- 为了提供一个全面的综述在ALS的肌痛性关节障碍.
- 突出诊断工具和治疗策略的进步.
- 强调数字语音生物标志物和人工智能在早期检测和管理中的作用.
主要方法:
- 临床表现,机制,诊断和治疗ALS相关性脱关节症的文献综述.
- 对数字语音生物标志物和人工智能应用的当前研究进行分析.
- 评估各种干预策略,包括语音技巧,手术选择,呼吸辅助和辅助设备.
主要成果:
- 由人工智能分析的数字语音生物标志物显示出对ALS早期和差异诊断的希望.
- 发言率下降可能会在确诊的ALS诊断之前出现,这表明早期干预的可能性.
- 存在多种治疗途径来改善声功能和生活质量.
结论:
- 通过高级语音分析早期识别脱节症对于ALS管理至关重要.
- 结合诊断,治疗和辅助通信设备的多方面的方法是必不可少的.
- 技术进步为改善ALS患者的治疗结果提供了新的希望.
相关概念视频
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Atherosclerosis IV: Nursing Management
51
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
51
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35


